Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. announced that Aziz Mottiwala will be leaving his position as Chief Commercial Officer and his employment with the company on July 15, 2026. Mottiwala is departing to pursue a new opportunity as the Chief Executive Officer of a public medical device company.

Tarsus Pharmaceuticals, Inc. announced the acquisition of iRenix Medical, Inc., a clinical-stage ophthalmic biopharmaceutical company. The acquisition brings IRX-101, an investigational ocular antiseptic designed to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The deal includes an upfront consideration of approximately $75 million, comprising $37.5 million in cash and $37.5 million in Tarsus common stock, plus potential milestone payments of up to $490 million. Positive Phase 2b/3 data for IRX-101 demonstrated significant reductions in pain and corneal damage compared to povidone-iodine, with a Phase 3 study expected to begin in the first half of 2027.

Tarsus Pharmaceuticals announced its management will participate in two upcoming investor conferences: the William Blair 46th Annual Growth Stock Conference and the 2026 Jefferies Global Healthcare Conference. Live webcasts and replays of these presentations will be accessible on the company's website. Tarsus Pharmaceuticals focuses on revolutionizing treatment for patients, starting with eye care, and has an FDA-approved product, XDEMVY, for Demodex blepharitis.

Tarsus Pharmaceuticals announced a new partnership with John Cena to raise awareness for Demodex blepharitis, a common but often overlooked eyelid disease. Cena, who experienced symptoms for years, will detail his journey with the condition and XDEMVY® (lotilaner ophthalmic solution) 0.25%, the first and only FDA-approved treatment. The campaign aims to encourage individuals to prioritize eye health and seek diagnosis for symptoms like eyelid redness, itching, and crusting, which affect millions of Americans.

Tarsus Pharmaceuticals, Inc. announced that its management plans to participate in three upcoming investor conferences in May 2026. These include the Bank of America Securities 2026 Health Care Conference on May 12th, the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19th, and the Stifel 2026 Virtual Ophthalmology Forum on May 26th. Live webcasts and replays of these presentations will be accessible on the events section of the Tarsus website.

Tarsus Pharmaceuticals reported a significant increase in total revenues for Q1 2026, reaching $162.1 million, more than double the previous year, primarily driven by strong product sales of XDEMVY. The company also narrowed its net loss to $7.0 million, down from $25.1 million in Q1 2025. Despite improved financial performance, Tarsus continues to incur losses and negative cash flows, highlighting ongoing capital requirements and dependence on XDEMVY's commercial success and pipeline development.

Tarsus Pharmaceuticals reported strong first quarter 2026 financial results, driven by significant growth in XDEMVY net product sales, which increased over 85% year-over-year to $145.4 million. The company reaffirmed its full-year 2026 guidance for XDEMVY sales at $670-700 million and reduced its net loss to $7.0 million. Tarsus also highlighted progress in its pipeline, including the initiation of a Phase 2 trial for TP-05 for Lyme disease prevention and regulatory approval for TP-03 (XDEMVY) in China.

Tarsus Pharmaceuticals, Inc. announced it will host a live webcast on Wednesday, May 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to report its first quarter 2026 financial results and provide a corporate update. A recorded version of the call will be available on the company's website for approximately 90 days. The company is advancing its pipeline, including XDEMVY for Demodex blepharitis, and TP-04 and TP-05 in Phase 2 for ocular rosacea and Lyme disease prevention, respectively.

Tarsus Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 25, 2026. Stockholders will vote on the election of four Class III directors, an advisory resolution to approve named executive officer compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. The Board of Directors unanimously recommends voting for all proposals.